Communication at the request of the FSMA on the transactions with Qliniq
Hyloris Reports Full Year Results for 2023 & Provides Business Outlook
Hyloris to Report 2023 Full-Year Results on 14 March 2024
Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients...
Hyloris and Purna Announce Positive Results from Phase 2 Trial in Acute VVC
Hyloris Broadens Pipeline with new Product Candidate for Vulvar Lichen Sclerosus (VLS) Equal Partnership with AFT Pharmaceuticals for Development of a Drug Releasing Mucoadhesive Film for VLS...
Orphan Drug Designation Granted to PTX-252 by U.S. FDA for the Treatment of AML
Liège, Belgium – December, 26 2023 – 6PM CET – Regulated information – Inside Information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces positive results from a pivotal clinical study for its proprietary Valacyclovir Oral Suspension. It allows for further preparation of a NDA1 for submission to the FDA expected in 2024.
Hyloris Broadens Pipeline with new Product Candidate in Burning Mouth Syndrome Equal Partnership with AFT Pharmaceuticals for Development of a Novel Locally-Acting Product Candidate in Burning Mouth...
Territorial expansion for a product candidate previously exclusively targeting the U.S.Kye Pharmaceuticals to register and commercialize in Canada Liège, Belgium “ 24 October 2023 “ 7AM CET “...